3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Gynecologic
5
Sarcoma
1
Plasma cell
1
Myeloid
1
Lymphoid
1
Conditions
Multiple Myeloma
47
Recurrence
10
Neoplasms, Plasma Cell
5
Sarcoma
2
Lymphoma, T-Cell, Peripheral
2
Lymphoma, Non-Hodgkin
2
Waldenstrom Macroglobulinemia
1
Vascular Neoplasms
1
Solitary Fibrous Tumors
1
Smooth Muscle Tumor
1
Smoldering Multiple Myeloma
1
Sarcoma, Clear Cell
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Osteosarcoma
1
Neurofibrosarcoma
1
Nerve Sheath Neoplasms
1
Neoplasms, Adipose Tissue
1
Neoplasms
1
Neoplasm, Residual
1
Myoepithelioma
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Large B-Cell, Diffuse
1
Liposarcoma, Myxoid
1
Liposarcoma
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Immunoglobulin Light-chain Amyloidosis
1
Hodgkin Disease
1
Histiocytoma, Angiomatoid Fibrous
1
Interventions
Trastuzumab
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
trametinib
1
selinexor
1
sapanisertib
1
relatlimab
1
pertuzumab
1
pemigatinib
1
pembrolizumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
defactinib
1
dabrafenib
1
copanlisib
1
capivasertib
1
binimetinib
1
adavosertib
1
X-Rays
1
Sunitinib
1
Specimen Handling
1
PF-05280014
1
Ontruzant
1
Ogivri
1
Nuclear Medicine Department, Hospital
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Endometrial Neoplasms
×
selinexor
×
Plasma cell
×
Clear all
NCT07215832
2026-03-02
KEAP
Karyopharm Therapeutics Inc
Available